1. Home
  2. ZLAB vs BILL Comparison

ZLAB vs BILL Comparison

Compare ZLAB & BILL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • BILL
  • Stock Information
  • Founded
  • ZLAB 2013
  • BILL 2006
  • Country
  • ZLAB China
  • BILL United States
  • Employees
  • ZLAB N/A
  • BILL N/A
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • BILL EDP Services
  • Sector
  • ZLAB Health Care
  • BILL Technology
  • Exchange
  • ZLAB Nasdaq
  • BILL Nasdaq
  • Market Cap
  • ZLAB 3.6B
  • BILL 4.3B
  • IPO Year
  • ZLAB 2017
  • BILL 2019
  • Fundamental
  • Price
  • ZLAB $34.55
  • BILL $43.70
  • Analyst Decision
  • ZLAB Buy
  • BILL Buy
  • Analyst Count
  • ZLAB 4
  • BILL 21
  • Target Price
  • ZLAB $47.37
  • BILL $62.89
  • AVG Volume (30 Days)
  • ZLAB 1.0M
  • BILL 2.1M
  • Earning Date
  • ZLAB 08-05-2025
  • BILL 05-08-2025
  • Dividend Yield
  • ZLAB N/A
  • BILL N/A
  • EPS Growth
  • ZLAB N/A
  • BILL N/A
  • EPS
  • ZLAB N/A
  • BILL N/A
  • Revenue
  • ZLAB $418,326,000.00
  • BILL $1,422,885,000.00
  • Revenue This Year
  • ZLAB $44.07
  • BILL $15.18
  • Revenue Next Year
  • ZLAB $49.13
  • BILL $12.31
  • P/E Ratio
  • ZLAB N/A
  • BILL N/A
  • Revenue Growth
  • ZLAB 43.72
  • BILL 14.52
  • 52 Week Low
  • ZLAB $16.01
  • BILL $36.55
  • 52 Week High
  • ZLAB $44.34
  • BILL $100.19
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 49.05
  • BILL 47.49
  • Support Level
  • ZLAB $36.36
  • BILL $41.30
  • Resistance Level
  • ZLAB $44.34
  • BILL $46.33
  • Average True Range (ATR)
  • ZLAB 1.45
  • BILL 1.45
  • MACD
  • ZLAB -0.16
  • BILL -0.17
  • Stochastic Oscillator
  • ZLAB 39.20
  • BILL 48.86

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About BILL BILL Holdings Inc.

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Share on Social Networks: